S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.35
+1.67
+10.01%
RLAY · Relay Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Relay Therapeutics Inc (RLAY)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$18.42
-0.03
(-0.19%)
● At close: October 21 at 4:00:00 PM EDT
$17.90
-0.51
(-2.77%)
Pre-Market:
4:38:35 AM EDT
DAY'S RANGE
$18.42
$18.20
$19.01
52-WEEK RANGE
$18.42
$5.95
$21.27
What's happening
- RLAY is down 0.19% today, trading at $18.42. — Live quote
- Volume today (114,556) is well below its 3-month average of 3,146,450. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.41 actual vs. $-0.40 estimated (-2.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 7
Buy 11
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RLAY
+118.09%
vs S&P 500
+105.31%
1-YEAR RETURN
RLAY
+158.40%
vs S&P 500
+143.84%
6-MONTH RETURN
RLAY
+14.53%
3-MONTH RETURN
RLAY
-4.40%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.41
Est. $-0.40
MISS -2.8%
2026-04-26 (Q1 2026)
$-0.41
Est. $-0.38
MISS -6.7%
2026-01-26 (Q4 2025)
$-0.32
Est. $-0.41
BEAT +22.4%
2025-10-26 (Q3 2025)
$-0.43
Est. $-0.42
MISS -1.5%
Valuation Measures & Ratios
Enterprise Value4$3.89B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)387.89
Price / Book74.53
EV4 / Revenue376.18
EV4 / EBITDA—
Profit Margin-2047.23%
Operating Margin-2222.65%
Return on Equity (ROE8)-42.27%
Return on Assets (ROA9)-38.67%
Avg Volume (3M)3,146,450
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $3.82B | $1.78B | $901.9M | $593.9M | $437.3M |
| P/E | -12.67 | -6.03 | -2.91 | -1.81 | -1.29 |
| Price/Sales | 948.83 | 156.47 | 107.93 | 71.07 | 24.72 |
| Price/Book | 4.29 | 2.77 | 1.48 | 0.89 | 0.61 |
| EV/Revenue | 918.73 | 138.45 | 96.97 | 57.44 | 19.43 |
| ROE | -33.88% | -45.92% | -50.96% | -49.24% | -46.98% |
| ROA | -31.17% | -42.15% | -46.22% | -44.97% | -42.38% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short46,746,942
Change from Prior Settlement+5.08%
% of Float—
Days to Cover (Short Ratio)12.59
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +158.4%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-10-08; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -48.3% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -2047.2%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RLAY
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $350.0K | $3.0M | $0 | $677.0K | $7.7M | $0 | $0 | $10.0M |
| Operating income | -$90.8M | -$78.6M | -$80.4M | -$76.8M | -$84.9M | -$96.4M | -$100.8M | -$90.4M |
| Net income | -$83.7M | -$73.3M | -$74.1M | -$70.4M | -$77.1M | -$88.1M | -$92.2M | -$81.4M |
| EPS (diluted) | $-0.41 | $-0.41 | $-0.43 | $-0.41 | $-0.46 | $-0.63 | $-0.69 | $-0.62 |
| EPS (basic) | $-0.41 | $-0.41 | $-0.43 | $-0.41 | $-0.46 | $-0.63 | $-0.69 | $-0.62 |
| Operating margin | -$25.9K | -$2.6K | — | -$11.4K | -$1.1K | — | — | -$903 |
| Net margin | -$23.9K | -$2.4K | — | -$10.4K | -$1.0K | — | — | -$813 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $967.5M | $699.6M | $621.3M | $670.0M | $728.8M | $799.4M | $871.3M | $930.1M |
| Total liabilities | $77.4M | $57.4M | $54.3M | $62.3M | $63.2M | $78.3M | $93.5M | $91.3M |
| Stockholders' equity | $890.0M | $642.2M | $567.1M | $607.7M | $665.7M | $721.1M | $777.8M | $838.9M |
| Total current assets | $928.1M | $658.5M | $578.3M | $624.0M | $680.4M | $739.7M | $809.2M | $865.1M |
| Total current liabilities | $50.8M | $29.8M | $25.6M | $32.6M | $32.5M | $37.1M | $50.7M | $47.0M |
| Cash & equivalents | $121.2M | $204.6M | $84.0M | $91.6M | $113.9M | $93.5M | $124.3M | $152.4M |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | $8.4M | $4.6M | $6.0M | $3.7M | $7.6M | $7.4M | $10.5M | $6.8M |
| Property, plant & equipment | $862.0K | $1.2M | $1.7M | $2.4M | $3.5M | $5.1M | $5.9M | $7.2M |
| Intangible assets | — | — | — | — | — | — | — | $2.3M |
| Accounts payable | $11.5M | $4.1M | $7.7M | $2.8M | $5.2M | $8.4M | $14.1M | $6.9M |
| Accrued liabilities | $34.1M | $20.9M | $13.6M | $25.1M | $23.2M | $21.0M | $21.2M | $33.2M |
| Deferred revenue (current) | — | — | — | — | — | — | $7.7M | — |
| Other current liabilities | $1.3M | $847.0K | $463.0K | $1.1M | $609.0K | $1.7M | $2.0M | $1.4M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $211.0K | $182.0K | $168.0K | $168.0K | $168.0K | $168.0K | $168.0K | $167.0K |
| Retained earnings | -$2.17B | -$2.09B | -$2.01B | -$1.96B | -$1.89B | -$1.82B | -$1.74B | -$1.66B |
| Accumulated other comprehensive income (loss) | -$1.6M | -$172.0K | $733.0K | $493.0K | -$163.0K | $38.0K | -$991.0K | $2.5M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$54.1M | -$51.1M | -$44.9M | -$62.1M | -$55.3M | -$73.2M | -$57.9M | -$75.1M |
| Investing cash flow | -$353.0M | $32.9M | $35.5M | $39.7M | $75.1M | $42.5M | $29.0M | -$126.2M |
| Financing cash flow | $323.7M | $138.8M | $934.0K | $17.0K | $653.0K | — | $800.0K | $218.9M |
| Free cash flow | -$54.1M | — | -$44.9M | -$62.1M | -$55.3M | -$73.6M | -$57.9M | -$75.3M |
| Capital expenditures | $0 | — | $1.0K | -$1.0K | $26.0K | $384.0K | $0 | $227.0K |
| Share-based compensation | $9.2M | $10.5M | $13.1M | $15.5M | $14.5M | $19.3M | $17.6M | $22.5M |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | — | — | — | — | — | — | — | -$4.3M |
| Purchases of investments | $471.3M | $50.9M | $34.0M | $58.1M | $8.9M | $22.0M | $75.1M | $265.1M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M |
| Operating income | -$302.7M | -$372.5M | -$373.0M | -$299.3M | -$364.7M |
| Net income | -$276.5M | -$337.7M | -$342.0M | -$290.5M | -$363.9M |
| EPS (diluted) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
| EPS (basic) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 |
| Operating margin | -$2.0K | -$3.7K | -$1.5K | -$21.7K | -$12.0K |
| Net margin | -$1.8K | -$3.4K | -$1.3K | -$21.0K | -$12.0K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $621.3M | $871.3M | $844.0M | $1.10B | $1.01B |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M | $110.6M |
| Stockholders' equity | $567.1M | $777.8M | $752.0M | $950.2M | $897.8M |
| Total current assets | $578.3M | $809.2M | $770.1M | $1.02B | $976.2M |
| Total current liabilities | $25.6M | $50.7M | $30.3M | $63.7M | $24.3M |
| Cash & equivalents | $84.0M | $124.3M | $143.7M | $151.8M | $280.1M |
| Accounts receivable | — | — | — | $306.0K | $403.0K |
| Other current assets | $6.0M | $10.5M | $3.3M | $3.3M | $1.8M |
| Property, plant & equipment | $1.7M | $5.9M | $10.9M | $11.6M | $6.5M |
| Intangible assets | — | — | $2.3M | $2.3M | $2.3M |
| Accounts payable | $7.7M | $14.1M | $9.2M | $10.6M | $8.3M |
| Accrued liabilities | $13.6M | $21.2M | $14.9M | $22.7M | $13.6M |
| Deferred revenue (current) | — | $7.7M | — | — | — |
| Other current liabilities | $463.0K | $2.0M | $1.2M | $26.2M | $396.0K |
| Other non-current liabilities | — | — | — | — | $15.0M |
| Common stock & paid-in capital | $168.0K | $168.0K | $127.0K | $121.0K | $109.0K |
| Retained earnings | -$2.01B | -$1.74B | -$1.40B | -$1.06B | -$768.1M |
| Accumulated other comprehensive income (loss) | $733.0K | -$991.0K | -$196.0K | -$10.4M | -$1.1M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$235.5M | -$249.1M | -$300.3M | -$229.5M | -$74.4M |
| Investing cash flow | $192.8M | -$41.1M | $257.6M | -$188.7M | -$479.5M |
| Financing cash flow | $1.6M | $270.2M | $34.8M | $289.9M | $388.1M |
| Free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M | -$77.9M |
| Capital expenditures | $410.0K | $2.0M | $4.1M | $9.1M | $3.5M |
| Share-based compensation | $62.4M | $94.1M | $86.0M | $56.1M | $48.5M |
| Change in accounts receivable | — | — | -$306.0K | -$97.0K | -$74.7M |
| Change in accounts payable | — | — | -$2.4M | $2.0M | $930.0K |
| Purchases of investments | $123.0M | $650.6M | $385.5M | $535.4M | $980.7M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RLAY as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers100.0%
Shares Outstanding202,849,466
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 27,904,963 | $522.1M | 13.76% | +0.0% | 2026-08-14 |
| FMR LLC | 20,110,113 | $376.3M | 9.91% | +444.2% | 2026-08-13 |
| Casdin Capital, LLC | 16,035,240 | $300.0M | 7.90% | +11.2% | 2026-08-14 |
| BlackRock, Inc. | 15,288,202 | $286.0M | 7.54% | +17.8% | 2026-08-07 |
| PERCEPTIVE ADVISORS LLC | 14,106,187 | $263.9M | 6.95% | +44.7% | 2026-08-14 |
| Commodore Capital LP | 12,000,000 | $224.5M | 5.92% | -29.4% | 2026-08-14 |
| State Street Corp | 10,125,381 | $189.5M | 4.99% | +62.4% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 8,964,423 | $167.7M | 4.42% | +21.3% | 2026-06-30 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 7,708,507 | $144.2K | 3.80% | +300.5% | 2026-08-14 |
| Nextech Invest Ltd. | 6,776,506 | $126.8M | 3.34% | +22.6% | 2026-08-14 |
| Bellevue Group AG | 6,185,970 | $115.7M | 3.05% | -20.6% | 2026-08-13 |
| GEODE CAPITAL MANAGEMENT, LLC | 4,726,576 | $88.4M | 2.33% | +34.6% | 2026-08-12 |
| TCG Crossover Management, LLC | 4,273,356 | $80.0M | 2.11% | +0.0% | 2026-08-12 |
| ALLIANCEBERNSTEIN L.P. | 4,095,600 | $40.8M | 2.02% | +2719.7% | 2026-08-14 |
| Morgan Stanley | 3,851,071 | $72.1M | 1.90% | +168.9% | 2026-08-11 |
| Siren, L.L.C. | 3,650,000 | $68.3M | 1.80% | +0.0% | 2026-08-13 |
| Goldman Sachs Group Inc | 3,408,701 | $63.8M | 1.68% | +34.1% | 2026-08-14 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 3,343,496 | $62.6M | 1.65% | +0.0% | 2026-08-12 |
| Kynam Capital Management, LP | 3,300,000 | $61.7M | 1.63% | +131.7% | 2026-08-14 |
| DIMENSIONAL FUND ADVISORS LP | 3,127,564 | $58.5M | 1.54% | +6.4% | 2026-08-11 |
| Spruce Street Capital LP | 2,984,125 | $55.8M | 1.47% | +0.0% | 2026-08-13 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,892,785 | $54.1M | 1.43% | +55.2% | 2026-06-30 |
| BAKER BROS. ADVISORS LP | 2,826,783 | $52.9M | 1.39% | +143.7% | 2026-08-14 |
| Bank Of America Corp /De/ | 2,695,108 | $50.4M | 1.33% | +39.1% | 2026-08-14 |
| MPM BioImpact LLC | 2,415,672 | $45.2M | 1.19% | +2.4% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-22 to 2026-10-07
Recent transactions
- Insiders have net sold 6,620,425 shares over the last 182 days, across 0 purchases and 22 sales.
- Most recent: Patel Sanjiv (President and CEO) — Open market sale of 48,199 shares on 2026-10-07.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)6,620,425 sh(22 txns)
Net Shares-6,620,425
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Patel Sanjiv | President and CEO | Open market sale | 2026-10-07 | 48,199 |
| Catinazzo Thomas | Chief Financial Officer | Open market sale | 2026-10-06 | 17,511 |
| Bergstrom Donald A | President, R&D | Open market sale | 2026-09-08 | 8,530 |
| Rahmer Peter | See remarks | Open market sale | 2026-08-26 | 4,508 |
| SVF Pauling (Cayman) Ltd | 10% owner | Open market sale | 2026-08-25 | 6,000,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-07 | Patel Sanjiv | President and CEO | Open market sale | 48,199 | $18.10 |
| 2026-10-06 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 17,511 | $18.58 |
| 2026-10-06 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 206 | $19.26 |
| 2026-09-08 | Bergstrom Donald A | President, R&D | Open market sale | 8,530 | $18.97 |
| 2026-09-08 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 17,717 | $18.94 |
| 2026-09-08 | Patel Sanjiv | President and CEO | Open market sale | 48,199 | $18.94 |
| 2026-08-26 | Rahmer Peter | See remarks | Open market sale | 4,508 | $20.03 |
| 2026-08-25 | SVF Pauling (Cayman) Ltd | 10% owner | Open market sale | 6,000,000 | $19.40 |
| 2026-08-17 | Patel Sanjiv | President and CEO | Open market sale | 48,199 | $20.33 |
| 2026-08-14 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 17,717 | $19.74 |
| 2026-07-28 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 1,459 | $18.61 |
| 2026-07-28 | Rahmer Peter | See remarks | Open market sale | 748 | $18.61 |
| 2026-07-28 | Bergstrom Donald A | President, R&D | Open market sale | 2,237 | $18.61 |
| 2026-07-07 | Patel Sanjiv | President and CEO | Open market sale | 48,199 | $19.58 |
| 2026-07-06 | Bergstrom Donald A | President, R&D | Open market sale | 8,660 | $18.71 |
| 2026-07-06 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 17,717 | $18.69 |
| 2026-06-30 | Patel Sanjiv | President and CEO | Grant / award | 3,056 | $6.95 |
| 2026-06-30 | Rahmer Peter | See remarks | Open market sale | 50,000 | $19.09 |
| 2026-06-30 | Rahmer Peter | See remarks | Grant / award | 3,056 | $6.95 |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 17,717 | $17.01 |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Option exercise | 56,323 | $5.04 |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 56,323 | $16.97 |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Option exercise | 61,563 | $5.22 |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 61,563 | $16.97 |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Option exercise | 51,560 | $4.45 |
| 2026-06-22 | Catinazzo Thomas | Chief Financial Officer | Open market sale | 51,560 | $16.97 |
| 2026-06-22 | Bergstrom Donald A | President, R&D | Option exercise | 93,456 | $4.12 |
| 2026-06-22 | Bergstrom Donald A | President, R&D | Open market sale | 93,456 | $16.94 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 09:06 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-08 | 4 | 2026-10-07 | View on SEC.gov → |
| 2026-10-08 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-08-28 | 4 | 2026-08-26 | View on SEC.gov → |
| 2026-08-28 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-14 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-30 | 4 | 2026-07-28 | View on SEC.gov → |
Recent news
Headlines about RLAY (Relay Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
(RLAY) as a Liquidity Pulse for Institutional Tactics
Stock Traders Daily · 2026-10-18 -
RLAY Nov 2026 18.000 call (RLAY261120C00018000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-18 -
Why Is RLAY Stock Rising Today?
Stocktwits · 2026-10-16 -
RLAY Nov 2026 20.000 call (RLAY261120C00020000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-16 -
Relay: The Recent Market Excitement Ignores The Reality Of Clinical Risks And Patent Cliffs
SeekingAlpha · 2026-10-16 -
RLAY Oct 2026 28.000 call (RLAY261016C00028000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
Relay Therapeutics Rally Fades As Short Squeeze Unwinds
TipRanks · 2026-10-15 -
What Could Go Wrong With Recursion Pharmaceuticals Stock?
Yahoo · 2026-10-08
No headlines in this category right now — try “All”.